97 related articles for article (PubMed ID: 1392125)
1. Serum levels of soluble interleukin-2 receptor in systemic and circumscribed scleroderma.
Zillikens D; Blum C; Dummer R; Hartmann AA; Burg G
Dermatology; 1992; 184(3):233-4. PubMed ID: 1392125
[No Abstract] [Full Text] [Related]
2. Increased levels of circulating intercellular adhesion molecule-1 in patients with localized scleroderma.
Ihn H; Fujimoto M; Sato S; Kikuchi K; Igarashi A; Soma Y; Takehara K
J Am Acad Dermatol; 1994 Oct; 31(4):591-5. PubMed ID: 7916356
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of serum levels of soluble interleukin-2 receptor in patients with localized scleroderma.
Ihn H; Sato S; Fujimoto M; Kikuchi K; Takehara K
Br J Dermatol; 1996 May; 134(5):843-7. PubMed ID: 8736323
[TBL] [Abstract][Full Text] [Related]
4. [Hemostasis in patients with circumscribed and systemic scleroderma].
Dovzhanskiĭ SI; Gerasimova MV
Vestn Dermatol Venerol; 1988; (1):41-3. PubMed ID: 3364021
[No Abstract] [Full Text] [Related]
5. Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma.
Ihn H; Sato S; Fujimoto M; Kikuchi K; Takehara K
Arch Dermatol Res; 1995; 287(2):193-7. PubMed ID: 7763091
[TBL] [Abstract][Full Text] [Related]
6. Circulating interleukin 1 beta and soluble interleukin 2 receptor: evaluation as markers of disease activity in scleroderma.
Patrick MR; Kirkham BW; Graham M; Harrision LC
J Rheumatol; 1995 Apr; 22(4):654-8. PubMed ID: 7791158
[TBL] [Abstract][Full Text] [Related]
7. Demonstration of interleukin 8 in serum samples of patients with localized scleroderma.
Ihn H; Sato S; Fujimoto M; Kikuchi K; Takehara K
Arch Dermatol; 1994 Oct; 130(10):1327-8. PubMed ID: 7944520
[No Abstract] [Full Text] [Related]
8. Serum levels of soluble interleukin 6 receptor and soluble gp130 are elevated in patients with localized scleroderma.
Nagaoka T; Sato S; Hasegawa M; Ihn H; Takehara K
J Rheumatol; 2000 Aug; 27(8):1917-21. PubMed ID: 10955333
[TBL] [Abstract][Full Text] [Related]
9. [Differential blood pictures in progressive and circumscribed scleroderma].
Roder H; Pinzer B
Dermatol Monatsschr; 1972 Jun; 158(6):417-20. PubMed ID: 5044634
[No Abstract] [Full Text] [Related]
10. Increased concentrations of soluble interleukin-2 receptor in the serum of patients with systemic sclerosis.
Airò P; Bettinzioli M; Gorla R; Cattaneo R
Ann Rheum Dis; 1991 Apr; 50(4):270-1. PubMed ID: 2029213
[No Abstract] [Full Text] [Related]
11. Serum renin and renin substrate levels in scleroderma.
Fleischmajer R; Gould AB
Proc Soc Exp Biol Med; 1975 Nov; 150(2):374-9. PubMed ID: 1208551
[No Abstract] [Full Text] [Related]
12. [Some data on the cytochemistry of peripheral blood neutrophils in scleroderma].
Shapiro AM; Guseva NG; Komissarova IA
Sov Med; 1971 May; 34(5):36-9. PubMed ID: 5159384
[No Abstract] [Full Text] [Related]
13. Cutaneous fibrinolytic activity in scleroderma.
Lotti T; Cerinic MM; Marmugi D; Fabbri P
Clin Exp Rheumatol; 1985; 3(3):249-53. PubMed ID: 4053443
[TBL] [Abstract][Full Text] [Related]
14. Significance of pentraxin-3 in patients with juvenile scleroderma.
Adrovic A; Sahin S; Barut K; Durmus S; Uzun H; Kasapcopur O
Clin Exp Rheumatol; 2017; 35 Suppl 106(4):221-222. PubMed ID: 28664833
[No Abstract] [Full Text] [Related]
15. [Serum proteins in sclerodermia (author's transl)].
Kobíková M; Fucíková T; Stáva Z
Cesk Dermatol; 1980 Oct; 55(5):295-300. PubMed ID: 7261076
[No Abstract] [Full Text] [Related]
16. Soluble CD8 antigen in systemic sclerosis.
Famularo G; Giacomelli R; Sacchetti S; Danese C; Luciani AM; Perego MA; Tonietti G
J Clin Lab Immunol; 1990 Jul; 32(3):109-12. PubMed ID: 1966946
[TBL] [Abstract][Full Text] [Related]
17. Circulating levels of soluble CD30 are increased in patients with localized scleroderma and correlated with serological and clinical features of the disease.
Ihn H; Yazawa N; Kubo M; Yamane K; Sato S; Fujimoto M; Kikuchi K; Soma Y; Tamaki K
J Rheumatol; 2000 Mar; 27(3):698-702. PubMed ID: 10743811
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of manganese superoxide dismutase in patients with localized scleroderma.
Jinnin M; Ihn H; Yazawa N; Asano Y; Yamane K; Tamaki K
Exp Dermatol; 2004 Jun; 13(6):357-60. PubMed ID: 15186321
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.
Asano Y; Ihn H; Yamane K; Yazawa N; Kubo M; Fujimoto M; Tamaki K
Arthritis Rheum; 2001 Jun; 44(6):1363-9. PubMed ID: 11407696
[TBL] [Abstract][Full Text] [Related]
20. Serum aminoterminal propeptide of type III procollagen in progressive systemic sclerosis and localized scleroderma.
Zachariae H; Halkier-Sørensen L; Heickendorff L
Acta Derm Venereol; 1989; 69(1):66-70. PubMed ID: 2563612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
